ArticleFrontiers in immunology2013
Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer.
Article in Frontiers in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- SUMOylation is destined for regulatory T cell-related immune dysregulation.Cell death discovery · 2026Review
- Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment.Frontiers in immunology · 2021Review
- Single-cell analysis reveals immune modulation and metabolic switch in tumor-draining lymph nodes.Oncoimmunology · 2020Article
- Immunometabolic Checkpoints of Treg Dynamics: Adaptation to Microenvironmental Opportunities and Challenges.Frontiers in immunology · 2019Review
- Functional Phenotypic Diversity of Regulatory T Cells Remaining in Inflamed Skin.Frontiers in immunology · 2019Article
- Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment.Frontiers in immunology · 2019Article
- Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma.Frontiers in oncology · 2018Review
- Retinaldehyde dehydrogenase 2 as a molecular adjuvant for enhancement of mucosal immunity during DNA vaccination.Vaccine · 2016Article
- Activation of myeloid dendritic cells, effector cells and regulatory T cells in lichen planus.Journal of translational medicine · 2016Article
- Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2015Article
- Induced regulatory T cells in inhibitory microenvironments created by cancer.Expert opinion on biological therapy · 2014Review
- Higher FOXP3-TSDR demethylation rates in adjacent normal tissues in patients with colon cancer were associated with worse survival.Molecular cancer · 2014Article
- Ubiquitous points of control over regulatory T cells.Journal of molecular medicine (Berlin, Germany) · 2014Review
- Thymus-Derived, Peripherally Derived, and in vitro-Induced T Regulatory Cells.Frontiers in immunology · 2014Article
- Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis.OncoimmunologyArticle
- 'Hardcore' OX40OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expansion of regulatory T cells (Treg) is a common event characterizing the vast majority of human and experimental tumors and it is now well established that Treg represent a crucial hurdle for a successful immunotherapy. Treg are currently classified, according to their origin, into thymus-derived Treg (tTreg) or peripherally induced Treg (pTreg) cells. Controversy exists over the prevalent mechanism accounting for Treg expansion in tumors, since both tTreg proliferation and de novo pTreg differentiation may occur. Since tTreg and pTreg are believed as preferentially self-specific or broadly directed to non-self and tumor-specific antigens, respectively, the balance between tTreg and pTreg accumulation may impact on the repertoire of antigen specificities recognized by Treg in tumors. The prevalence of tTreg or pTreg may also affect the outcome of immunotherapies based on tumor-antigen vaccination or Treg depletion. The mechanisms dictating pTreg induction or tTreg expansion/stability are a matter of intense investigation and the most recent results depict a complex landscape. Indeed, selected Treg subsets may display peculiar characteristics in terms of stability, suppressive function, and cytokine production, depending on microenvironmental signals. These features may be differentially distributed between pTreg and tTreg and may significantly affect the possibility of manipulating Treg in cancer therapy. We propose here that innovative immunotherapeutic strategies may be directed at diverting unstable/uncommitted Treg, mostly enriched in the pTreg pool, into tumor-specific effectors, while preserving systemic immune tolerance ensured by self-specific tTreg.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.